Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (217)	6/9/1999 7:36:00 PM
From: Biomaven	Respond to of 52153

An interesting snip from a good site for pharma comment: labpuppy.com Expected EPS (earnings per share) growth for US pharmaceutical companies over the next three-to-five years (from assorted analyst estimates) American Home Products - 14-16% Amgen - 13-16% (acceleration starts in 2001 with NESP) Bristol-Myers Squibb - 13-14% (weighed down by non-pharma divisions) Johnson & Johnson – 12-13% Eli Lilly - 14-18% (depends on how they deal with Prozac) Merck - 8-14%(depends on how they deal with numerous patent expirations) Monsanto - 20-25% (reliance on Celebrex) Pfizer - 19-20% Pharmacia & Upjohn - 13-14% Schering-Plough - 15-16% Warner-Lambert - 17-21% Top 10 pharmaceutical companies (in terms of pharmaceutical revenue) Merck Aventis Glaxo Wellcome AstraZeneca Pfizer Novartis Bristol-Myers Squibb Eli Lilly Roche Johnson & Johnson